During the past decade, Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin" #1 sponsor was "Clavis Pharma" with 1 trials, followed by "Genentech, Inc." with 1 trials sponsored, "Technische Universität Dresden" with 1 trials sponsored, "University of Ulm" with 1 trials sponsored and "Wuerzburg University Hospital" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator, "Celltrion Healthcare Co., LTD" with 1 trials as a collaborator, "ClinAssess GmbH" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin" are "Acute Myeloid Leukemia (AML)" (1 trials), "Marginal Zone Lymphoma" (1 trials), "Metastatic Breast Cancer" (1 trials), "Previously Untreated Symptomatic Multiple Myeloma" (1 trials) and "Refractory AML" (1 trials). Many other conditions were trialed in "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin" in a lesser frequency.

Most popular intervention types in "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin" are "Drug" (5 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (1 trials), "Elacytarabine" (1 trials), "Investigator's Choice" (1 trials), "Lenalidomide, Bortezomib" (1 trials) and "Pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".